ArticleJournal of translational medicine2026
UBC9-mediated regulation of K144 ubiquitination of Lamin A and its implications for hepatocellular carcinoma.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatocellular carcinoma (HCC) is a lethal malignancy with limited treatment options. UBC9, the sole E2 conjugating enzyme in the SUMOylation pathway, is frequently overexpressed in HCC, yet its specific role in hepatocarcinogenesis remains unclear. This study aims to elucidate the regulatory mechanism of UBC9 in HCC, specifically focusing on its crosstalk with Lamin A (LMNA) via SUMOylation and ubiquitination.
methodsWe analyzed UBC9 and LMNA expression in HCC tissues using TCGA and GEO datasets and evaluated their correlation with clinical outcomes. A doxycycline-inducible shRNA system was established in Hep3B and Huh-7 cell lines to assess the effects of UBC9 knockdown on cell proliferation, migration, and invasion. Proteomics and ubiquitin-proteomics analyses were performed to identify downstream targets. Mechanisms of LMNA regulation were investigated using immunoprecipitation, site-directed mutagenesis (K144R), and cycloheximide chase assays. Xenograft mouse models were used to validate findings in vivo.
resultsUBC9 was significantly upregulated in HCC tissues, and high levels correlated with poor prognosis. Knockdown of UBC9 suppressed HCC cell proliferation, migration, and invasion in vitro and tumor growth in vivo. Proteomic screening identified LMNA as a key downstream target. UBC9 depletion led to reduced LMNA protein stability via increased ubiquitination without affecting its mRNA levels. We identified Lysine 144 (K144) as a novel ubiquitination site on LMNA; the K144R mutation or enhanced SUMOylation prevented LMNA degradation. Rescue experiments demonstrated that LMNA knockdown partially reversed the oncogenic phenotype induced by UBC9 overexpression.
conclusionsUBC9 promotes HCC progression by stabilizing LMNA through SUMOylation, which prevents ubiquitin-mediated degradation at the K144 site. The UBC9-LMNA axis represents a critical regulatory mechanism and a promising therapeutic target for hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.